Engflag

Ainedix

Quick links to important sections

Ainedix

Ainedix_ID

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ainedix

What is Ainedix? (Identity and Classification)

Quick Facts

Property Description
Active ingredient Nimesulide
Form Tablets, Oral Suspension, Granules, Topical Gel
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common purpose Relief of pain, inflammation, and fever
Origin Synthetic compound (Sulfonanilide derivative)

Ainedix is the trade name for a medicinal preparation whose active component is Nimesulide, which is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Ainedix is fundamentally designed to provide relief from symptoms involving inflammation, pain, and fever by targeting the chemical pathways responsible for these responses.

The active ingredient, Nimesulide, is a chemically synthetic compound that belongs specifically to the sulfonanilide subclass of NSAIDs. Nimesulide is particularly recognized for its characteristic as a preferential Cyclooxygenase-2 (COX-2) inhibitor, which sets it apart from traditional non-selective NSAIDs by focusing its action primarily on the enzyme responsible for generating inflammatory mediators.

Composition, Origin, and Available Forms

The Ainedix preparation is a single-ingredient product, containing only Nimesulide as the therapeutic substance. The medication is made available in several forms, including oral tablets, granules for oral suspension, and a topical gel. The diversity of dosage forms allows for a range of routes of administration, such as the oral route for systemic absorption or the dermal route for localized effect.

Nimesulide maintains effectiveness across these various routes of administration, facilitating its use in managing acute symptoms. The application of the medication is intended to reduce inflammation and relieve acute discomfort.

What is the General Purpose of Ainedix? (High-Level Benefit)

The general purpose of Ainedix is to provide symptomatic relief through a triple therapeutic action: achieving an anti-inflammatory effect, an analgesic effect (pain relief), and an antipyretic effect (fever reduction). For example, it is commonly utilized for the general relief of acute pain and associated inflammation resulting from soft tissue injury. This overall benefit is achieved because Nimesulide prevents the excessive synthesis of prostaglandins, the chemical signals that trigger the body's inflammatory and febrile responses.

As an anti-inflammatory and antirheumatic agent, the drug’s function is defined by its ability to control the body's response to inflammation and manage pain.

Regulatory References

  1. European Medicines Agency
  2. [WHO ATC Classification]

What side effects are possible with Ainedix?

Ainedix's safety profile is documented by regulatory authorities, with adverse reactions formally classified by frequency and grouped into System-Organ Classes (SOC). The most frequently reported adverse effects (classified as Common) primarily involve the Gastrointestinal System, including diarrhoea, nausea, and vomiting, alongside transient elevation of liver enzyme levels (transaminases).

Documented Serious Adverse Reactions

Official regulatory documents emphasize the potential for serious adverse reactions, particularly within the Hepatobiliary System. These include rare reports of severe liver injury, such as fulminant hepatitis and hepatic failure. Serious reactions related to the gastrointestinal tract, such as ulceration, bleeding, or perforation, are also documented risks, which can occur at any time during treatment.

Special Population and Duration Safety Notes

Specific regulatory constraints exist for certain patient groups. The use of Ainedix is contraindicated in individuals with pre-existing hepatic impairment, a history of hepatotoxic reactions to the drug, or severe renal impairment. Older adults are noted in prescribing information as being generally more susceptible to NSAID adverse effects, including serious gastrointestinal and organ function issues. Gastrointestinal risks are often linked to long-term exposure to NSAIDs and must be considered throughout the course of treatment. This structured profile allows health authorities to convey the necessary limitations on use to keep the risk profile acceptable.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Ainedix (Nimesulide) is documented in regulatory sources to initially present with signs common to NSAID toxicity. These manifestations include gastrointestinal disturbance, such as nausea, vomiting, and epigastric pain (upper abdominal discomfort). In less severe cases, somnolence (drowsiness) has also been reported. Severe clinical presentations can involve convulsions, hypotension, and coma.

The regulatory profile outlines a risk of severe systemic outcomes following an overdose. The most significant serious risks documented are acute liver failure—which may necessitate emergency liver transplantation—and acute renal failure. Management is strictly symptomatic and supportive, as no specific antidote is known. Measures like gastric lavage or administration of activated charcoal may be considered in a clinical setting to reduce absorption following acute ingestion.

When to Seek Urgent Medical Attention

  • Immediate medical attention must be sought following the acute ingestion of a substantial excessive dose.
  • If signs compatible with hepatic injury develop during treatment—such as loss of appetite, persistent tiredness, abdominal pain, or dark urine—treatment must be discontinued immediately, and a physician must be informed.
  • Monitoring of renal and hepatic function is required following an overdose incident.

Therapeutic Uses of Ainedix

Main Therapeutic Uses

Ainedix is a medication primarily utilized for the management of symptoms associated with various inflammatory and painful conditions. Its primary applications include:

  • Rheumatoid Arthritis: Long-term management of inflammation, swelling, and joint pain in adults.
  • Osteoarthritis: Relief of pain and improvement of physical function in patients with degenerative joint disease.
  • Ankylosing Spondylitis: Reduction of spinal pain and stiffness associated with this chronic inflammatory condition.
  • Acute Pain Management: Short-term relief of moderate to severe pain, such as that following surgical procedures or acute musculoskeletal injuries.
  • Primary Dysmenorrhea: Treatment of menstrual cramps and associated discomfort.

Therapeutic Benefits

The active mechanism of Ainedix provides several clinical benefits focused on improving the patient's quality of life and functional capacity:

Reduction of Inflammation

By targeting specific inflammatory pathways, the medication helps decrease the swelling and redness in affected tissues. This is particularly beneficial for chronic conditions where persistent inflammation can lead to progressive joint damage.

Analgesic Effect

Ainedix acts to raise the pain threshold, providing relief from both localized and systemic pain. This allows patients to engage more effectively in daily activities and physical therapy.

Improvement in Mobility

By alleviating pain and reducing joint stiffness, the medication helps restore a greater range of motion. This improvement in mobility is a key factor in maintaining independence and physical health in patients with chronic arthritic conditions.

Fever Reduction

In certain clinical contexts, the medication may be used for its antipyretic properties to reduce elevated body temperature associated with inflammatory responses.

Regulatory References

  1. European Medicines Agency's therapeutic overview

Eligibility and Restrictions for Use

Who can and cannot use Ainedix?

Official regulatory documents define the eligible patient population for Ainedix as strictly limited to adults and adolescents 12 years of age and older. Use is contraindicated for all children under 12 years.

Contraindicated Populations

Ainedix must not be used by populations with specific health conditions, including:

  • Organ Impairment: Patients with any degree of hepatic impairment or severe renal impairment (Creatinine Clearance < 30 mL/min). Use is permitted in mild to moderate renal impairment.
  • Gastrointestinal and Bleeding Risk: Individuals with an active peptic ulcer, a history of recurrent ulceration or gastrointestinal bleeding, cerebrovascular bleeding, severe coagulation disorders, or severe heart failure.
  • Allergy and History: Patients with known hypersensitivity to Nimesulide or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), or a history of hepatotoxic reactions to the medicine.
  • Reproductive Status: Use is contraindicated during the third trimester of pregnancy and breastfeeding. It is not recommended for women attempting to conceive.

Eligibility-Related Restrictions

Use in elderly patients is permitted, but appropriate clinical monitoring is advisable due to increased susceptibility to adverse effects. The overall eligibility profile is strictly defined by age, organ function, prior drug history, and bleeding risk, as stipulated by regulatory authorities.

What should I know about interactions with other medicines?

Ainedix Interactions with other medicines and products

The official regulatory profile for Ainedix (Nimesulide) identifies several constraints regarding co-administration with other substances. Certain combinations are formally designated as contraindicated, including use with alcohol, other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and any medicinal products documented as hepatotoxic.

Pharmacokinetic and Pharmacodynamic Interactions

Ainedix is documented to cause a pharmacokinetic interaction as an inhibitor of Cytochrome P450 2C9 (CYP2C9). This effect can lead to an increase in the plasma concentrations and systemic exposure of other drugs that are CYP2C9 substrates, such as lithium and phenytoin.

Pharmacodynamic interactions primarily involve an additive risk for certain adverse outcomes. Co-administration with anticoagulants (e.g., Warfarin) and antiplatelet agents increases the systemic risk of bleeding. The combination with Diuretics or Antihypertensives (ACE inhibitors, Angiotensin II Antagonists) may result in reduced efficacy of these agents and an increased risk of nephrotoxicity. The profile also notes that interactions with medicines like Methotrexate result in a documented increase in plasma levels, while the exposure of Furosemide may be reduced.

Specific population-dependent interaction cautions apply to elderly patients and individuals with renal impairment, where the severity of interaction outcomes, particularly bleeding and renal impairment, is officially noted as heightened.

Mechanism of Action

Dual Mechanism: GABA A Potentiation and L-type Ca^2+ Blockade

Ainedix achieves its physiological effects through a dual mechanism, primarily acting as a positive allosteric modulator of the GABA A receptor complex and a non-competitive blocker of voltage-gated L-type Ca^2+ channels.

At the GABA A receptor, Ainedix enhances the effects of the inhibitory neurotransmitter GABA, promoting Cl^- ion influx. This causes hyperpolarization of central nervous system neurons, modulating signal transmission within neural circuits and resulting in CNS depression.

Simultaneously, by blocking L-type Ca^2+ channels, the drug impedes Ca^2+ ion entry, which facilitates neurotransmitter release and muscle contraction. This action limits the propagation of signals in motor and nociceptive pathways, resulting in reduced motor signaling and modulated nociceptive pathway activity.

Dosage and Administration Information

How Ainedix is Used in Clinical Practice

This section describes the administration guidelines for Ainedix, focusing on usage principles and dosing.

Administration Scope and Dosing

Instruction Principle of Use
Route of Administration The medicine is administered systemically via the oral route (tablets, granules) or locally via the topical (dermal) route (gel).
Standard Oral Dose The standard adult oral unit dose is 100 mg.
Dosing Frequency Systemic oral dosing follows a twice daily (b.i.d.) schedule.
Maximum Daily Dose The maximum recommended oral daily intake is restricted to 200 mg.
Timing of Intake Oral formulations must be taken after meals to align with official use instructions.

Duration and Specific Usage Conditions

Oral Ainedix is intended strictly for short-term use. The overall treatment course is limited to a maximum of 15 days. This principle mandates that the medication be used at the minimum effective dose and for the shortest possible duration necessary for the relevant clinical scenario.

Population Rules

Official prescribing information for systemic use indicates that no general dose reduction is typically required for older adults (the elderly). For adolescents aged 12 to 18 years, the dosage principle aligns with the standard adult regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ainedix

Evidence for Use in Acute Pain

The research exploring the use of Ainedix for acute physical discomfort has largely been built upon short-term Randomized Controlled Trials (RCTs) and subsequent analyses. These studies were designed to monitor and collect data related to specific and temporary pain episodes, such as those following a minor surgical procedure or related to a soft tissue injury. Research was conducted during periods of increased symptom activity and focused on populations of adults and adolescents (aged 12 and older).

Studies monitored outcomes related to physical discomfort by using standardized measurements like pain intensity scales. Findings describe patterns observed in the studies regarding changes in these measured scores over short time intervals. This evidence primarily describes patterns for acute, short-term use.

Evidence for Treatment of Menstrual Pain (Primary Dysmenorrhoea)

Research explored the use of Ainedix in conditions associated with acute or disruptive episodes, specifically primary dysmenorrhoea (menstrual pain). The evidence base includes randomized, controlled clinical trials that monitored patient-reported outcomes describing perceived discomfort during the acute menstrual episode. Some pharmacological studies also explored outcomes linked to specific biochemical markers.

Research Gaps and Limitations

Official regulatory reports and peer-reviewed syntheses highlight several key areas where the research evidence is limited. The follow-up durations were limited across most trials, consistently covering only a maximum of 15 consecutive days of therapy. Long-term effects are not fully established, as the evidence structure was specifically tailored to evaluate short-term symptom changes.

Furthermore, research focusing on secondary dysmenorrhoea and outcomes for certain populations like the elderly or pediatric groups below 12 years of age is generally less frequently observed in the regulatory record. The historical evidence for long-term use in conditions like osteoarthritis is viewed by regulators as inconsistent with current short-term usage restrictions.

Key Studies & References

  1. World Health Organization (WHO): ATC Classification M01AX17 (Nimesulide)

Frequently Asked Questions (FAQ)

Common questions about Ainedix (FAQ)

Q: How quickly does Ainedix typically start working after I begin taking it?

A: Clinical studies and official documentation describe Ainedix as having a relatively quick onset of action. Monitored effects on discomfort have been observed within 15 minutes of intake. The active ingredient typically reaches its highest concentration in the bloodstream within two to three hours after being taken.

Q: How long does the effect of a dose of Ainedix usually last?

A: Official product information describes a twice-daily dosing principle. The elimination half-life of the active ingredient, which is the time it takes for half of the drug to be eliminated from the body, is typically documented between 1.8 and 4.7 hours. The main metabolized form of the medicine has a slightly longer half-life, ranging from 3.2 to 6 hours.

Q: Can Ainedix be taken for a long period of time?

A: The official guidelines for oral use strictly limit treatment duration to the shortest possible time, not exceeding 15 consecutive days. This restriction is in place because risks related to the liver and gastrointestinal tract are documented to be associated with prolonged exposure to this class of medicine.

Q: Is Ainedix the same type of medication as other common treatments for the same condition?

A: Ainedix is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its active ingredient is described in official documents as a preferential COX-2 inhibitor, meaning it focuses its action mainly on one specific enzyme pathway. This feature contributes to its pharmacological distinction from non-selective NSAIDs.

Q: What is the difference between Ainedix and other similar drugs mentioned online?

A: Official information indicates that the active ingredient in Ainedix is an NSAID that works by preferentially inhibiting the COX-2 enzyme. This characteristic helps define its mechanism of action and sets it apart from other NSAIDs that may not share this preferential action.

Q: What is the mechanism of action of Ainedix in simple terms?

A: Ainedix works through a dual process that affects nerve signaling. It enhances the effect of a natural body chemical that calms the central nervous system, and it blocks channels that help communicate pain and movement signals, thereby contributing to its anti-inflammatory and pain-relieving effects.

Q: Why does Ainedix sometimes need to be taken with food?

A: The official prescribing information specifies that oral formulations should be taken after meals. This administration rule is generally advised to help minimize the likelihood of common gastrointestinal side effects, such as nausea or stomach upset, which are documented adverse reactions for this medicine.

Q: Is it common to feel tired or dizzy when starting Ainedix?

A: Official regulatory documentation includes warnings about the possibility of dizziness or somnolence (drowsiness) as potential undesirable effects. These effects are classified in the product’s safety profile and may occur in some individuals.

Q: What happens if I forget to take my Ainedix dose?

A: Regulatory guidance for this twice-daily medication suggests that if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. Official guidance states that a double dose should not be taken to make up for a missed one.

Q: Can Ainedix affect my ability to drive or operate machinery?

A: Regulatory documentation advises that if a person experiences undesirable effects such as dizziness or somnolence (drowsiness) while taking the medicine, they should refrain from driving or operating machinery. This is a common safety warning for medications that affect the central nervous system.

Q: Where can I find the official regulatory information about Ainedix?

A: Official regulatory information about Ainedix can be accessed by searching for the active ingredient, Nimesulide, on the public-facing websites of government drug authorities. Examples of such authorities include the European Medicines Agency (EMA) and the National Library of Medicine (NIH) in its related databases.

Q: Is Ainedix a controlled substance?

A: Ainedix is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) based on its chemical structure and pharmacological action. It is not designated as a controlled substance in official regulatory drug databases.

Q: Are there any genetic factors that might affect how Ainedix works for me?

A: Regulatory documents note that the active ingredient, Nimesulide, acts as an inhibitor of the enzyme Cytochrome P450 2C9 (CYP2C9). This enzyme is critical for processing certain co-administered drugs. Genetic variations in this enzyme can influence how other medicines taken simultaneously are processed by the body.

Q: Is Ainedix known to cause allergic reactions?

A: Ainedix is officially contraindicated for individuals with known hypersensitivity to its active ingredient or other NSAIDs. Documented manifestations of hypersensitivity can include skin reactions such as urticaria (hives) or angioedema.

Q: Are there different restrictions for men vs. women using Ainedix?

A: Yes, official regulatory restrictions specifically contraindicate the use of Ainedix during the third trimester of pregnancy and while breastfeeding. It is also noted as not recommended for women who are actively trying to conceive.

Q: Is it possible to have a negative reaction to Ainedix after using it for a long time?

A: The oral use of Ainedix is strictly limited to a maximum of 15 days because risks are documented to increase with prolonged exposure. Risks, particularly those related to the gastrointestinal tract (like bleeding or ulceration) and liver injury, are associated with long-term use of this medicine class.

How should Ainedix be stored and disposed of?

How to Store and Dispose of Ainedix?

Storage Requirements

Ainedix must be stored at controlled room temperature, typically between 20 C and 25 C. To maintain product stability, it is required to keep the medicine in its original container, ensure it is tightly closed, and protect it from both light and moisture in a dry place. In accordance with safety regulations, the medicine must be stored strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Ainedix should be disposed of according to local and national regulations. Patients are generally advised not to flush the medicine down the toilet or throw it directly into household trash. The recommended disposal method is to return the product to an authorized drug take-back program or pharmacy collection point. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance, sealed in a bag, and then discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ainedix found in:

A-Z Index: